Search results:
Found 3
Listing 1 - 3 of 3 |
Sort by
|
Choose an application
Inequity starts before birth and is programmed in part by nutritional exposures. If these exposures occur around the time of conception, during pregnancy, and/or in infancy or childhood (all critical periods of development) they may alter a child’s health trajectory and impact risk for impaired cognition and learning, and cardiometabolic, immune, and neuropsychiatric diseases and disorders. This Special Issue on “Early Life Nutrition and Future Health” has the following aims: 1) understand the origins of offspring health inequities from an early nutritional perspective; 2) uncover new insights into the environmental, biological, and social mechanisms that underpin these health outcomes in offspring; and 3) present novel targets and approaches to optimise health trajectories and prevent chronic diseases and disorders in later life and across generations. The research projects included herein highlight novel mechanistic, epidemiologic, and intervention studies that target key windows where nutrition has the greatest influence on future health (preconception, prenatal, and postnatal periods) and that explore vulnerable populations and animal models of early life nutritional programming.
reduced litter size --- postnatal calcium homeostasis --- adult bone health --- milk composition --- developmental origins of health and disease (DOHaD) --- gut microbiota --- non-communicable disease --- nutrient-sensing signal --- nutrition --- oxidative stress --- pregnancy --- reprogramming --- undernutrition --- abdominal obesity --- fetal --- infant --- adulthood --- folic acid supplementation --- pregnancy --- epidemiology --- social inequalities --- short-chain fatty acid (SCFA) --- pH --- dietary fibre --- gut health --- prebiotic --- malnutrition --- gut barrier --- development --- pregnancy --- prebiotic --- gut-brain --- programming --- microbiota --- L-cell --- eating behavior --- pregnancy --- postpartum --- dietary intake --- energy intake --- supplements --- dietary reference intakes (DRIs) --- diet quality --- Healthy Eating Index --- sugars --- fruit juices --- life-course epidemiology --- infant --- child --- human milk --- human milk oligosaccharides --- phospholipids --- sphingomyelin --- gangliosides --- LC–MS
Choose an application
Iron is an essential element for almost all organisms, a cofactor playing a crucial role in a number of vital functions, including oxygen transport, DNA synthesis, and respiration. However, its ability to exchange electrons renders excess iron potentially toxic, since it is capable of catalyzing the formation of highly poisonous free radicals. As a consequence, iron homeostasis is tightly controlled by sophisticated mechanisms that have been partially elucidated. Because of its biological importance, numerous disorders have been recently linked to the deregulation of iron homeostasis, which include not only the typical disorders of iron overload and deficiency but also cancer and neurodegenerative diseases. This leads iron metabolism to become an interesting therapeutic target for novel pharmacological treatments against these diseases. Several therapies are currently under development for hematological disorders, while other are being considered for different pathologies. The therapeutic targeting under study includes the hepcidin/ferroportin axis for the regulation of systemic iron homeostasis, complex cytosolic machineries for the regulation of the intracellular iron status and its association with oxidative damage, and reagents exploiting proteins of iron metabolism such as ferritin and transferrin receptor. A promising potential target is a recently described form of programmed cell death named ferroptosis, in which the role of iron is essential but not completely clarified. This Special Issue has the aim to summarize the state-of-the-art, and the latest findings published in the iron field, as well as to elucidate future directions.
cinnamic acid derivatives --- soybean seed ferritin --- iron release --- binding ability --- Fe2+-chelating activity --- reducibility --- adverse event profile --- anaemia --- bioengineering --- labile iron --- intravenous iron --- iron-carbohydrate complex --- iron processing --- iron metabolism --- infection --- innate immunity --- hepcidin --- ferritin --- anemia of inflammation --- pharmaceutical targets --- iron deficiency anemia --- nutrient iron --- oral iron therapy --- FeSO4 --- NaFeEDTA --- non-transferrin-bound iron (NTBI) --- developing countries --- Indonesia --- neurodegeneration --- mitochondria --- therapy --- heme --- haem --- Iron-sulfur --- Friedreich Ataxia --- Oxidative stress --- Iron chelators --- iron deficiency --- anemia --- cancer --- hepcidin --- patient blood management --- malaria --- iron deficiency --- hepcidin --- TNF --- children --- Africa --- Anemia --- iron deficiency --- oral iron salts --- intravenous iron --- Sucrosomial® iron --- M cells --- bioavailability --- tolerability --- efficacy --- iron --- gut microbiota --- iron supplementation --- iron transporters --- mucosal immunity --- SCFA --- intestinal inflammation --- inflammatory bowel disease (IBD) --- colorectal cancer --- oxidative stress --- anaemia --- cardiovascular disease --- chronic kidney disease --- IV iron therapy --- bone homeostasis --- iron overload --- iron deficiency --- osteoclast --- osteoblast --- osteoporosis --- neurodegeneration with brain iron accumulation --- iron chelation therapy --- multifunctional iron chelators --- fluorescent iron chelator --- 3-hydroxy-4-pyridinone --- fluorophore --- rhodamine --- membrane interactions --- bacteria --- antibacterial activity --- histidine --- iron --- anemia --- oxidative stress --- kidney --- chelation --- iron --- retina --- age-related macular degeneration (AMD) --- iron --- lipid --- obesity --- cancer --- neurodegeneration --- iron chelation --- phlebotomy --- NCOA4 --- ferritinophagy --- iron homeostasis --- erythropoiesis --- ferroptosis --- cancer --- Tfr2 --- iron metabolism --- hepcidin --- erythropoiesis --- SNC --- ferritin --- iron mobilization --- chaotropes --- flavin nucleotide --- electron transfer --- kinetics --- ferritin --- iron --- iron delivery --- nanotechnology --- nanocage --- drug delivery --- inflammation --- serum biomarker --- iron metabolism --- hepcidin --- ferroportin --- hemochromatosis --- anemia --- hepcidin --- iron deficiency anemia --- iron dextran --- neonatal period --- pig --- supplementation --- Alzheimer’s disease --- neuroinflammation --- neurodegeneration --- cytokines --- neuroimmune responses --- iron --- genetic hemochromatosis --- non transferrin bound iron --- hepcidin --- ferroportin --- venesections --- Anemia of chronic disease --- anemia of inflammation --- hepcidin --- anti-hepcidin therapy --- iron supplementation --- macrophage --- central nurse macrophage --- red pulp macrophage --- Kupffer cell --- iron metabolism --- erythropoiesis --- erythroblastic islands --- erythrophagocytosis --- inflammation --- iron homeostasis --- lung diseases --- oxygen sensing --- hypoxia --- ferritin --- hereditary hyperferritinemia --- hereditary hypoferritinemia --- iron metabolism --- cataracts syndrome --- neurodegenerative disease --- n/a --- iron --- neurodegeneration --- NBIA --- hepcidin --- iron --- lung --- acute lung injury --- COPD --- lung infection --- cystic fibrosis --- iron --- anaemia --- infection --- malaria --- immunity --- brain development --- growth --- microbiome --- hepcidin --- ferritin --- iron supplementation --- infants --- children --- low and middle income countries --- liver --- iron --- hepcidin --- Mek/Erk --- Hfe --- Bmp/Smad --- iron --- mycobacteria --- immunity --- Alzheimer’s disease --- iron homeostasis --- ferroptosis --- senescence --- chelators --- macrophages --- iron --- metabolism --- inflammation --- iron --- ferritin --- acute kidney injury --- chronic kidney disease --- vascular calcification --- iron --- hepcidin --- ferroportin --- Interleukin-6 --- infection --- rheumatoid arthritis --- iron homeostasis --- iron absorption --- non-haem iron --- flavonoids --- developmental --- iron deficiency anemia --- neonatal --- transferrin receptor --- treatment --- hemochromatosis --- HFE --- natural history --- T lymphocytes --- MHC --- CD8+ T cells --- prevention --- iron homeostasis --- hepcidin --- protein binding --- peritoneal dialysis --- iron --- hepcidin --- iron regulatory proteins --- cardiomyocyte --- chronic heart failure --- pulmonary arterial smooth muscle cells --- pulmonary arterial hypertension --- iron --- brain --- neurophysiology --- cognition --- social behavior --- didox --- iron chelators --- antitumor compound --- iron metabolism --- RRM2 --- SLC40A1 --- ferroportin --- iron overload --- non-HFE --- ferritin --- hemochromatosis --- iron --- chelation --- neurodegenerative diseases --- pituitary --- brain --- hemopexin --- heme homeostasis --- iron homeostasis --- hemolysis --- haptoglobin --- ferroptosis --- inflammation --- biomarker --- heme oxygenase --- liver --- microbiome --- trauma --- hemorrhage --- iron metabolism --- hepcidin --- iron homeostasis --- ferroportin --- n/a
Choose an application
Iron is an essential element for almost all organisms, a cofactor playing a crucial role in a number of vital functions, including oxygen transport, DNA synthesis, and respiration. However, its ability to exchange electrons renders excess iron potentially toxic, since it is capable of catalyzing the formation of highly poisonous free radicals. As a consequence, iron homeostasis is tightly controlled by sophisticated mechanisms that have been partially elucidated. Because of its biological importance, numerous disorders have been recently linked to the deregulation of iron homeostasis, which include not only the typical disorders of iron overload and deficiency but also cancer and neurodegenerative diseases. This leads iron metabolism to become an interesting therapeutic target for novel pharmacological treatments against these diseases. Several therapies are currently under development for hematological disorders, while other are being considered for different pathologies. The therapeutic targeting under study includes the hepcidin/ferroportin axis for the regulation of systemic iron homeostasis, complex cytosolic machineries for the regulation of the intracellular iron status and its association with oxidative damage, and reagents exploiting proteins of iron metabolism such as ferritin and transferrin receptor. A promising potential target is a recently described form of programmed cell death named ferroptosis, in which the role of iron is essential but not completely clarified. This Special Issue has the aim to summarize the state-of-the-art, and the latest findings published in the iron field, as well as to elucidate future directions.
cinnamic acid derivatives --- soybean seed ferritin --- iron release --- binding ability --- Fe2+-chelating activity --- reducibility --- adverse event profile --- anaemia --- bioengineering --- labile iron --- intravenous iron --- iron-carbohydrate complex --- iron processing --- iron metabolism --- infection --- innate immunity --- hepcidin --- ferritin --- anemia of inflammation --- pharmaceutical targets --- iron deficiency anemia --- nutrient iron --- oral iron therapy --- FeSO4 --- NaFeEDTA --- non-transferrin-bound iron (NTBI) --- developing countries --- Indonesia --- neurodegeneration --- mitochondria --- therapy --- heme --- haem --- Iron-sulfur --- Friedreich Ataxia --- Oxidative stress --- Iron chelators --- iron deficiency --- anemia --- cancer --- hepcidin --- patient blood management --- malaria --- iron deficiency --- hepcidin --- TNF --- children --- Africa --- Anemia --- iron deficiency --- oral iron salts --- intravenous iron --- Sucrosomial® iron --- M cells --- bioavailability --- tolerability --- efficacy --- iron --- gut microbiota --- iron supplementation --- iron transporters --- mucosal immunity --- SCFA --- intestinal inflammation --- inflammatory bowel disease (IBD) --- colorectal cancer --- oxidative stress --- anaemia --- cardiovascular disease --- chronic kidney disease --- IV iron therapy --- bone homeostasis --- iron overload --- iron deficiency --- osteoclast --- osteoblast --- osteoporosis --- neurodegeneration with brain iron accumulation --- iron chelation therapy --- multifunctional iron chelators --- fluorescent iron chelator --- 3-hydroxy-4-pyridinone --- fluorophore --- rhodamine --- membrane interactions --- bacteria --- antibacterial activity --- histidine --- iron --- anemia --- oxidative stress --- kidney --- chelation --- iron --- retina --- age-related macular degeneration (AMD) --- iron --- lipid --- obesity --- cancer --- neurodegeneration --- iron chelation --- phlebotomy --- NCOA4 --- ferritinophagy --- iron homeostasis --- erythropoiesis --- ferroptosis --- cancer --- Tfr2 --- iron metabolism --- hepcidin --- erythropoiesis --- SNC --- ferritin --- iron mobilization --- chaotropes --- flavin nucleotide --- electron transfer --- kinetics --- ferritin --- iron --- iron delivery --- nanotechnology --- nanocage --- drug delivery --- inflammation --- serum biomarker --- iron metabolism --- hepcidin --- ferroportin --- hemochromatosis --- anemia --- hepcidin --- iron deficiency anemia --- iron dextran --- neonatal period --- pig --- supplementation --- Alzheimer’s disease --- neuroinflammation --- neurodegeneration --- cytokines --- neuroimmune responses --- iron --- genetic hemochromatosis --- non transferrin bound iron --- hepcidin --- ferroportin --- venesections --- Anemia of chronic disease --- anemia of inflammation --- hepcidin --- anti-hepcidin therapy --- iron supplementation --- macrophage --- central nurse macrophage --- red pulp macrophage --- Kupffer cell --- iron metabolism --- erythropoiesis --- erythroblastic islands --- erythrophagocytosis --- inflammation --- iron homeostasis --- lung diseases --- oxygen sensing --- hypoxia --- ferritin --- hereditary hyperferritinemia --- hereditary hypoferritinemia --- iron metabolism --- cataracts syndrome --- neurodegenerative disease --- n/a --- iron --- neurodegeneration --- NBIA --- hepcidin --- iron --- lung --- acute lung injury --- COPD --- lung infection --- cystic fibrosis --- iron --- anaemia --- infection --- malaria --- immunity --- brain development --- growth --- microbiome --- hepcidin --- ferritin --- iron supplementation --- infants --- children --- low and middle income countries --- liver --- iron --- hepcidin --- Mek/Erk --- Hfe --- Bmp/Smad --- iron --- mycobacteria --- immunity --- Alzheimer’s disease --- iron homeostasis --- ferroptosis --- senescence --- chelators --- macrophages --- iron --- metabolism --- inflammation --- iron --- ferritin --- acute kidney injury --- chronic kidney disease --- vascular calcification --- iron --- hepcidin --- ferroportin --- Interleukin-6 --- infection --- rheumatoid arthritis --- iron homeostasis --- iron absorption --- non-haem iron --- flavonoids --- developmental --- iron deficiency anemia --- neonatal --- transferrin receptor --- treatment --- hemochromatosis --- HFE --- natural history --- T lymphocytes --- MHC --- CD8+ T cells --- prevention --- iron homeostasis --- hepcidin --- protein binding --- peritoneal dialysis --- iron --- hepcidin --- iron regulatory proteins --- cardiomyocyte --- chronic heart failure --- pulmonary arterial smooth muscle cells --- pulmonary arterial hypertension --- iron --- brain --- neurophysiology --- cognition --- social behavior --- didox --- iron chelators --- antitumor compound --- iron metabolism --- RRM2 --- SLC40A1 --- ferroportin --- iron overload --- non-HFE --- ferritin --- hemochromatosis --- iron --- chelation --- neurodegenerative diseases --- pituitary --- brain --- hemopexin --- heme homeostasis --- iron homeostasis --- hemolysis --- haptoglobin --- ferroptosis --- inflammation --- biomarker --- heme oxygenase --- liver --- microbiome --- trauma --- hemorrhage --- iron metabolism --- hepcidin --- iron homeostasis --- ferroportin --- n/a
Listing 1 - 3 of 3 |
Sort by
|
2020 (3)